Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
1 May 2012 |
Main ID: |
EUCTR2008-003740-11-ES |
Date of registration:
|
24/11/2008 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Estudio Fase IV, multinacional, multicéntrico, doble ciego, doble simulación, randomizado, de grupos paralelos, controlado, sobre la combinación de dosis fijas de Dipropionato de Beclometasona 100 µg más Fumarato de Formoterol 6 µg pMDI con propelente HFA-134A (CHF1535, FOSTER®) versus Fluticasona 250 µg más Salmeterol 50 µg IPS (SERETIDE® DISKUS®) como tratamiento de mantenimiento de pacientes asmáticos controlados.
A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS. - FACTO study
|
Scientific title:
|
Estudio Fase IV, multinacional, multicéntrico, doble ciego, doble simulación, randomizado, de grupos paralelos, controlado, sobre la combinación de dosis fijas de Dipropionato de Beclometasona 100 µg más Fumarato de Formoterol 6 µg pMDI con propelente HFA-134A (CHF1535, FOSTER®) versus Fluticasona 250 µg más Salmeterol 50 µg IPS (SERETIDE® DISKUS®) como tratamiento de mantenimiento de pacientes asmáticos controlados.
A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS. - FACTO study |
Date of first enrolment:
|
23/01/2009 |
Target sample size:
|
452 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003740-11 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: yes
Other trial design description: Double dummy
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
France
|
Germany
|
Netherlands
|
Spain
| | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Written informed consent obtained 2. Adult male and female (equal to and between 18 and 65 years) 3. Clinical diagnosis of controlled asthma according to Global Strategy for Asthma Management and Prevention (GINA) revised version 2007 in the previous week before study entry: - no daytime symptoms (twice or less/week) - no limitations of activities - no nocturnal symptoms/awakenings - no need for reliever/rescue medications (twice or less/week) - lung function (FEV1) greater than or equal to 80% predicted or personal best (if known) 4. Patients treated with fluticasone 500 µg + salmeterol 100 µg daily for greater than or equal to 4 weeks 5. A co-operative attitude and ability to correctly use the device and to complete the diary cards Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Inability to carry out pulmonary function testing; 2. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) as defined by the National Heart Lung and Blood Institute/World Health Organisation (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; 3. History of near fatal asthma; 4. Evidence of severe asthma exacerbation or symptomatic infection of the lower airways in the previous six months; 5. Three or more courses of oral corticosteroids or hospitalisation due to asthma during the previous 6 months; 6. Patients treated with long-acting Beta2-agonists (LABAs) other than salmeterol, anticholinergics, and leukotriene antagonists during the previous 4 weeks; 7. Current smokers or recent (less than one year) ex-smokers defined as smoking at least 15 packs/year; 8. Clinically significant or unstable concurrent disease : e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; significant other pulmonary disease; cardiovascular disease; gastrointestinal disease; neurological disease; haematological disease, autoimmune disorders, that may interfere with patient?s safety, compliance, or study evaluations, according to the investigators opinion; 9. Patients with a serum potassium value below or equal to 3.5 mEq/L 10. Patients with QTc interval (Bazetts formula) higher than 450 msec at screening visit 1; 11. Cancer or any chronic diseases with prognosis < 2 years; 12. Female subjects: pregnant or with active desire to be pregnant, lactating mother or lack of efficient contraception in a subject with child-bearing potential (i.e. contraceptive methods other than oral contraceptives, IUD, tubal ligature). A pregnancy test in urine is to be carried out in women of a fertile age at screening 13. Significant alcohol consumption or drug abuse; 14. Patients treated with beta-blockers as regular use; 15. Patients treated with monoamine oxidase inhibitor, tricyclic antidepressants and Selective Serotonin Re-uptake Inhibitors (SSRIs), unless already taken at stable doses at the screening visit 16. Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients; 17. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study; 18. Patients who received any investigational new drug within the last 12 weeks; 19. Patients with asthma exacerbations during the run-in period will also be excluded from the study.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Asma
Asthma MedDRA version: 9.1
Level: LLT
Classification code 10003553
Term: Asthma
|
Intervention(s)
|
Trade Name: FOSTER Pharmaceutical Form: Pressurised inhalation, solution INN or Proposed INN: FORMOTEROL FUMARATO DIHIDRATO Other descriptive name: FORMOTEROL FUMARATO DIHIDRATO Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 6- INN or Proposed INN: BECLOMETASONA DIPROPIONATO CAS Number: 5534-09-8 Other descriptive name: BECLOMETASONE DIPROPIONATE Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Pressurised inhalation, solution Route of administration of the placebo: Inhalation use
Trade Name: SERETIDE Accuhaler 50/250 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: SALMETEROL HIDROXINAFTOATO Other descriptive name: SALMETEROL HIDROXINAFTOATO Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 50- INN or Proposed INN: FLUTICASONA PROPIONATO CAS Number: 80474-14-2 Other descriptive name: FLUTICASONE PROPIONATE Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed Route of administration of the placebo: Inhalation use
|
Primary Outcome(s)
|
Main Objective: To demonstrate the equivalence in terms of FEV1 between CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily) and an equipotent dose of Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily) in asthmatic patients already controlled on fluticasone plus salmeterol, 500/100 µg /daily.
|
Primary end point(s): pre-dose morning FEV1 measured at clinic visit 5
|
Secondary Objective: To evaluate the efficacy of the two treatments in terms of pulmonary function, use of rescue medication, maintaining asthma control, to evaluate the safety profile through adverse events (AEs) and adverse drug reactions (ADRs) reporting, overnight urinary cortisol-creatinine ratio (OUCC), vital signs, and to assess treatment costs trough a cost minimisation analysis, comparing the total asthma-related direct medical costs and indirect costs in patients allocated to CHF1535 or to Seretide® Diskus®.
|
Secondary ID(s)
|
CCD-0806-PR-0032
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|